000143008 001__ 143008
000143008 005__ 20240229112539.0
000143008 0247_ $$2doi$$a10.1007/s10549-019-05188-x
000143008 0247_ $$2pmid$$apmid:30826935
000143008 0247_ $$2ISSN$$a0167-6806
000143008 0247_ $$2ISSN$$a1573-7217
000143008 0247_ $$2altmetric$$aaltmetric:57507798
000143008 037__ $$aDKFZ-2019-00633
000143008 041__ $$aeng
000143008 082__ $$a610
000143008 1001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b0$$eFirst author$$udkfz
000143008 245__ $$aHealth-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany.
000143008 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V.$$c2019
000143008 3367_ $$2DRIVER$$aarticle
000143008 3367_ $$2DataCite$$aOutput Types/Journal article
000143008 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1560327294_13323
000143008 3367_ $$2BibTeX$$aARTICLE
000143008 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143008 3367_ $$00$$2EndNote$$aJournal Article
000143008 520__ $$aLittle is known about breast cancer (BC) survivors' health-related quality of life (HRQoL) > 5 or even > 10 years past diagnosis. It is of interest whether, in the long run, survivors' HRQoL aligns with that of the general population. Study objectives were to (1) compare disease-free BC survivors' HRQoL to that of non-cancer controls, and (2) compare long-term survivors (LTS, 5-9 years post-diagnosis), very long-term survivors (VLTS, ≥ 10 years post-diagnosis), and controls with respect to their HRQoL.The samples of 2647 disease-free BC survivors (5-16 years post-diagnosis) and 1005 population controls were recruited in German multi-regional population-based studies. HRQoL was assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Differences in HRQoL were assessed with multiple regression, controlling for age and education.Disease-free BC survivors < 80 years (at survey) reported overall global health status/quality of life comparable to controls, but statistically significant lower physical, role, emotional, social, and cognitive functioning. They also indicated more fatigue, insomnia, dyspnoea, and financial difficulties. However, differences were only of trivial or small clinical relevance. At age 80-89, no differences between BC survivors and controls were observed. Deficits in emotional and cognitive functioning and some symptoms (e.g. insomnia and fatigue) persist, as both LTS and VLTS reported more detriments than controls.In view of the persistent, small but significant detriments in disease-free BC survivors' cognitive and emotional functioning and higher symptom burden, possibilities to prevent detriments from becoming chronic should be explored.
000143008 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143008 588__ $$aDataset connected to CrossRef, PubMed,
000143008 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa$$b1$$udkfz
000143008 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b2$$udkfz
000143008 7001_ $$aBertram, Heike$$b3
000143008 7001_ $$aEberle, Andrea$$b4
000143008 7001_ $$aHolleczek, Bernd$$b5
000143008 7001_ $$aPritzkuleit, Ron$$b6
000143008 7001_ $$aWaldeyer-Sauerland, Mechthild$$b7
000143008 7001_ $$aWaldmann, Annika$$b8
000143008 7001_ $$aZeissig, Sylke Ruth$$b9
000143008 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b10$$udkfz
000143008 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b11$$udkfz
000143008 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b12$$eLast author$$udkfz
000143008 773__ $$0PERI:(DE-600)2004077-5$$a10.1007/s10549-019-05188-x$$n2$$p499-510$$tBreast cancer research and treatment$$v175$$x1573-7217$$y2019
000143008 909CO $$ooai:inrepo02.dkfz.de:143008$$pVDB
000143008 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143008 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143008 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143008 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000143008 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000143008 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000143008 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143008 9141_ $$y2019
000143008 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143008 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST CANCER RES TR : 2017
000143008 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143008 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143008 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143008 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143008 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143008 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143008 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143008 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143008 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143008 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143008 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143008 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lCancer Survivorship$$x0
000143008 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x1
000143008 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000143008 980__ $$ajournal
000143008 980__ $$aVDB
000143008 980__ $$aI:(DE-He78)C071-20160331
000143008 980__ $$aI:(DE-He78)C070-20160331
000143008 980__ $$aI:(DE-He78)C120-20160331
000143008 980__ $$aUNRESTRICTED